Technology Prognosis

tracking technologies before you have to make a decision

Prognosis is a horizon scanning service that monitors emerging health technologies as they go through clinical trial development and the regulatory approval process.

View a sampling of our Prognosis reports.

Eversense Continuous Glucose Monitor

June 22, 2018 Technology Prognosis

The Eversense CGM is a continuous glucose monitor with implantable sensor for measuring glucose levels continually for up to 90 days in adults aged 18 years and older with either type 1 or type 2 diabetes. The Eversense CGM System consists of 3 components: an implantable cylindrical glucose sensor, a wearable smart transmitter, and a handheld device running a mobile medical application. The transmitter is worn over the implanted sensor for continuous readout of glucose data, but can be removed and replaced without the need for sensor replacement. The Eversense CGM system works in tandem with a mobile application that...

Monarch eTNS for Attention-Deficit/Hyperactivity Disorder

June 21, 2018 Technology Prognosis

The Monarch eTNS system is a non-invasive nerve stimulation device proposed for the treatment of ADHD in children, adolescents, and adults. The system consists of an external pulse generator which is connected to a self-adhesive conductive patch. The patch is applied to the forehead, and when the device is activated, bilateral, high frequency nerve stimulation is delivered to the V1 branch of the trigeminal nerve. Patients can adjust the level of stimulation, and typically use the device at night while sleeping.

Inspiris Resilia Aortic Valve

June 15, 2018 Technology Prognosis

The Inspiris Resilia is a replacement aortic valve comprised of 3 elements: Resilia tissue, VFit technology, and Carpentier-Edwards Perimount Magna Ease valve design. Carpentier-Edwards is an established, proven valve design; VFit is a new, proprietary platform that is designed for future adaptation for valve-in-valve procedures. Resilia tissue is a new, first-of-its-kind tissue platform that utilizes integrity preservation technology intended to provide improved anticalcification properties. Resilia consists of bovine pericardium that has been transformed via this novel integrity preservation process. The process eliminates the need for valve preservation in liquid solutions, which prevents the exposure to free aldehyde groups that occurs...

ReCell Autologous Cell Harvesting Device

June 14, 2018 Technology Prognosis

The ReCell Autologous Cell Harvesting Device is a single-use kit containing all of the components for point-of-care rapid processing of a small split-thickness autologous skin sample into a suspension of non-cultured mixed skin cells for immediate delivery via a spray applicator onto a burn wound following surgical excision. The cell suspension graft is designed to proliferate rapidly and migrate in the wound bed. It covers a treatment area up to 80 times the area of the donor skin sample.

Mogamulizumab (Proposed Name Poteligeo)

June 6, 2018 Technology Prognosis

Mogamulizumab is an intravenously administered, humanized immunoglobulin G1 monoclonal antibody proposed for the treatment of patients with mycosis fungoides or Sézary syndrome who have failed to adequately respond to at least 1 systemic therapy. Mogamulizumab targets CC chemokine receptor 4 (CCR4), a novel target for immunotherapy. CCR4 is frequently expressed on the surface of tumor cells of patients with CTCL, as well as with adult T-cell leukemia-lymphoma, and is selectively expressed in other subtypes of peripheral T-cell lymphoma (PTCL).